Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03186508
Other study ID # R01HL092910
Secondary ID R01HL092910
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date September 30, 2023

Study information

Verified date January 2024
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Enhancing children's sleep may be a novel approach for prevention of obesity and cardiovascular (CV) disturbance. Observational studies with children demonstrate that short sleep increases risk of obesity and other CV risk factors. Randomized controlled trials with children 8-11 years old demonstrate that enhancing sleep duration leads to positive changes in eating and activity behaviors and weight status, particularly for children who enhance their sleep the most. Enhancing sleep may be particularly important for racial minority children and those from lower socioeconomic backgrounds given their increased risk for short sleep, obesity and CV risk factors. In this study two active obesity preventive interventions will be evaluated: a) enhancing sleep alone (Optimize Sleep [OS]), and b) enhancing sleep along with eating and activity behaviors that have demonstrated efficacy for obesity prevention and are implicated in self-regulatory pathways related to sleep (i.e., energy dense snack foods and beverages, TV viewing, and physical activity) (OS-Plus). Two hundred four children 6-11 years old who are primarily African American/black, primarily from low socioeconomic backgrounds, and who sleep < 9.5 hours/night into a 12-month study will be enrolled. Children will be randomly assigned to either OS or OS-Plus. Over the 6-month treatment phase, all children will attend an 8-session treatment; monthly phone contacts will occur during maintenance (6-12 months). Primary aim is to determine the efficacy of OS-Plus relative to OS on change in body mass index z-score (BMIz) at end of treatment. Secondary aims will assess efficacy of OS-Plus relative to OS on additional cardiometabolic risk factors, eating and activity behaviors. Exploratory aims will assess maintenance of effects at 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 149
Est. completion date September 30, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 11 Years
Eligibility Inclusion Criteria: 1. Caregiver-reported child age of 6-11 years 2. < 9.5 Hours time-in-bed for sleep most days/week 3. BMI for age and gender > 25th percentile (but no greater than 100% overweight) 4. Understanding of and ability to complete protocol 5. Self-reported caregiver age of 18 years and primary caregiver at bedtimes/wake times 6. Likes food used in the eating regulation paradigms 7. Willingness to be randomized to either treatment condition. Exclusion Criteria: 1. Diagnosable sleep disorder 2. Medication use or diagnosis of medical or psychiatric condition that may impact sleep/weight status 3. Current or planned treatment for weight control 4. Allergies or dietary restrictions that would prevent consumption of foods used in the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Optimize Sleep (OS)
All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 "sleep challenges" (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.
Optimize Sleep-Plus (OS-Plus)
All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 "sleep challenges" (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.

Locations

Country Name City State
United States Temple University Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Temple University National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in BMIz change in body mass index z-score (accounting for child age and sex) Change from baseline BMIz at 6 months
Secondary Change in Body Composition change in body composition (% body fat) will be estimated by air displacement plethysmography (BOD POD®; Life Measurement Instruments, Concord, CA) Change from baseline percent body fat at 6 months
Secondary Change in Waist Circumference Change in measured waist circumference Change from baseline waist circumference at 6 months
Secondary Change in Insulin Resistance Change in the homeostatic model assessment of insulin resistance (HOMA-IR) Change from baseline HOMA-IR at 6 months
Secondary Change in Blood Glucose Levels 2-hour blood glucose levels measured within the context of an oral glucose tolerance test Change from baseline blood glucose levels at 6 months
Secondary Change in Non-HDL cholesterol (non-HDL-C) Total cholesterol (TC) minus HDL-C, includes LDL-C, VLDL-C, and atherogenic apo-B containing lipoproteins Change from baseline in Non-HDL-C at 6 months
Secondary Change in Insulin Sensitivity Index (ISI) Insulin Sensitivity Index measured within the context of an oral glucose tolerance test Change from baseline ISI at 6 months
Secondary Change in Sleep Period Wrist-worn actigraphy Change from baseline in the sleep period at 6 months
Secondary Change in Caloric Intake 24-hr dietary recalls on two days used to estimate caloric intake Change from baseline in caloric intake at 6 months
Secondary Change in Food Reinforcement Measured using a validated computer activity (Behavioral Choice Task), which assesses motivation for a food reward Change from baseline in food reinforcement at 6 months
Secondary Change in Eating in the Absence of Hunger (EAH) Food consumed within the context of the eating in the absence of hunger paradigm Change from baseline in EAH at 6 months
Secondary Change in Percent Time spent in Moderate to Vigorous Physical Activity (MVPA) Waist-worn accelerometer Change from baseline in MVPA at 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2